Development of lipid-based microsuspensions for improved ophthalmic delivery of gentamicin sulphate

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Tangari P, Khurana S. Basics of ocular drug delivery systems. Int. J. Res. Pharm. Biomed. Sci. 2(4), 1541–1552 (2011).
  Google Scholar
• 2. Yamaguchi M, Yasueda SI, Isowaki A. Formulation of an ophthalmic lipid emulsion containing an anti–inflammatory steroidal drug, difuprednate. Int. J. Pharm. 301(1–2), 121–128 (2005).
  Medline CASGoogle Scholar
• 3. Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J. Pharmacol. Exp. Ther. 370(3), 602–624 (2019).
  Medline CASGoogle Scholar
• 4. Kapoor Y, Chauhan A. Ophthalmic delivery of cyclosporine A from Brij-97 microemulsion and surfactant laden p–HEMA hydrogels. Int. J. Pharm. 361(1–2), 222–229 (2008).
  Medline CASGoogle Scholar
• 5. Nisha S, Deepak K. An insight to ophthalmic drug delivery system. Int. J. Pharm. Sci. Res. 3(2), 9–13 (2012).
  Google Scholar
• 6. Gaudana R, Jwala J, Boddu SHS, Mitra AK. Perspective in ocular drug delivery. Pharm. Res. 26(5), 1197–1216 (2009). •• Presents new insight into ocular drug delivery.
  Medline CASGoogle Scholar
• 7. Shen J, Gan L, Zhu C et al. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. Int. J. Pharm. 412(1–2), 115–122 (2011).
  Medline CASGoogle Scholar
• 8. Friedrich I, Reichl S, Müller-Goymann CC. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solution (SRMS). Int. J. Pharm. 305, 167–175 (2005).
  Medline CASGoogle Scholar
• 9. Friedrich I, Papantoniou I, Müller-Goymann CC. Physicochemical characterization of a reverse micellar solution after loading with different drugs. Pharmazie 55, 755–758 (2000).
  Medline CASGoogle Scholar
• 10. Chime SA, Onyishi IV. Solidified reverse micellar solution (SRMS): a novel approach for controlling drug release from various lipid-based drug delivery systems. Afr. J. Biotechnol. 12(52), 7138–7146 (2013).
  CASGoogle Scholar
• 11. Kenechukwu FC, Umeyor EC, Momoh MA et al. Evaluation of gentamicin-entrapped solid lipid microparticles formulated with a biodegradable homolipid from Capra hircus. Trop. J. Pharm. Res. 13(18), 1999–1205 (2014). • Presents an earlier work on gentamicin microparticles.
  Google Scholar
• 12. Uronnachi EM, Ogbonna JDN, Kenechukwu FC, Momoh MA, Attama AA, Okore VC. Pharmacokinetics and biodistribution of zidovudine loaded in a solidified reverse micellar delivery system. Int. J. Drug Del. 5, 73–80 (2013).
  CASGoogle Scholar
• 13. Ogbonna JDN, Nzekwe IT, Kenechukwu FC, Nwobi CS, Amah JI, Attama AA. Development and evaluation of chloroquine phosphate microparticles using solid lipid as a delivery carrier. J. Drug Discov. Dev. Deliv. 2(1), 1011 (2015).
  Google Scholar
• 14. Ogbonna JDN, Kenechukwu FC, Nwobi CS, Chibueze OS, Attama AA. Formulation, in vitro and in vivo evaluation of halofantrine-loaded solid lipid microparticles. Pharm. Dev. Technol. 20(8), 941–948 (2015).
  Medline CASGoogle Scholar
• 15. Agbo CP, Umeyor CE, Kenechukwu FC et al. Formulation design, in vitro and anti-malarial investigations of artemether and lumenfantrine-entrapped solid lipid microparticles. Drug Dev. Ind. Pharm. 42(10), 1708–1721 (2016).
  Medline CASGoogle Scholar
• 16. Attama AA, Kenechukwu FC, Onuigbo EB et al. Solid lipid nanoparticles encapsulating a fluorescent marker (coumarin 6) and antimalarials – artemether and lumefantrine: evaluation of cellular uptake and antimalarial activity. Eur. J. Nanomed. 8(3), 129–138 (2016).
  CASGoogle Scholar
• 17. Thackaberry EA et al. The safety evaluation of long-acting ocular delivery systems. Drug Discov. Today 24, 1539–1550 (2019). •• Discussed important safety issues associated with ocular delivery systems.
  Medline CASGoogle Scholar
• 18. Sharma A et al. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye 33, 1359–1361 (2019).
  MedlineGoogle Scholar
• 19. Short B. Selected aspects of ocular toxicity studies with a focus on high quality pathology reports: a pathology/toxicology consultant's perspective. Toxicol. Pathol. 49(3), 673–699 (2021).
  MedlineGoogle Scholar
• 20. Wessels U et al. Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection. Bioanalysis 10, 803–814 (2018).
  CASGoogle Scholar
• 21. Wakshull E et al. Advancements in understanding immunogenicity of biotherapeutics in the intraocular space. AAPS J. 19, 1656–1668 (2017).
  MedlineGoogle Scholar
• 22. Irigoyen C et al. Endophthalmitis following intravitreal injections. Graefes. Arch. Clin. Exp. Ophthalmol. 250, 499–505 (2012).
  Medline CASGoogle Scholar
• 23. Umeyor CE, Kenechukwu FC, Ogbonna JDN, Chime SA, Attama AA. Preparation of novel solid lipid microparticles loaded with gentamicin and its evaluation in vitro and in vivo. J. Microencapsul. 29(3), 296–307 (2012). • Highlights incorporation of gentamicin into lipid microparticles.
  Medline CASGoogle Scholar
• 24. Umeyor CE, Kenechukwu FC, Ogbonna JDN, Chime SA, Attama AA. Investigation of solidified reverse micellar systems as novel carriers for oral delivery of gentamicin. J. Pharm. Res. 5(9), 4914–4920 (2012).
  CASGoogle Scholar
• 25. United States Pharmacopoeial Convention. The United States Pharmacopeia (USP) 35. 945, MD, USA, 339–342 (2015).
  Google Scholar
• 26. Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin or mucous membranes. J. Pharmacol. Exp. Ther. 82, 377–390 (1944).
  CASGoogle Scholar
• 27. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticles formulation using human cornea construct. Int. J. Pharm. 355, 307–313 (2008). •• Presents a new idea on drug delivery to the eye.
  Medline CASGoogle Scholar
• 28. Wilson CG, Zhu YP, Kurmala P, Rao LS, Dhillon B. Ophthalmic drug delivery. In: Drug Delivery and Targeting. Hillery AMLloyd AWSwarbrick J (Eds). Taylor & Francis, NY, USA, 329–354 (2001).
  Google Scholar
• 29. Lorenzo CA, Hiratani H, Concheiro A. Contact lens for drug delivery. Achieving sustained release with novel systems. Am. J. Drug Deliv. 4(3), 131–151 (2006).
  Google Scholar
• 30. United States Pharmacopeial Convention. The United States Pharmacopeia, Test Solutions (2015). http://www.pharmacopeia.cn/v29240/usp29nf24s0_m34850.html. Accessed on 23/07/2021
  Google Scholar
• 31. Souto EB, Dias-Ferreira J, López-Machado A et al. Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents. Pharmaceutics 11, 460–488 (2019). •• Presents new insight into ocular drug delivery.
  CASGoogle Scholar
• 32. Pharmaceutical Society of Great Britain. The Pharmaceutical Codex Incorporating the British Pharmacopoiea (11th Edition). The Pharmaceutical Press, London, UK, 387 (1979).
  Google Scholar
• 33. Remington. The Science and Practice of Pharmacy (22nd Edition). Allen LV Jr (Ed.). The Pharmaceutical Press, London, UK, 3056 (2012).
  Google Scholar
• 34. Short BG. Safety evaluation of ocular drug delivery formulations: Techniques and practical considerations. Toxicol. Pathol. 36, 49–62 (2008).
  Medline CASGoogle Scholar